Quarterly Activities and Cashflow Report

ADELAIDE, Australia, and CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 30 June 2023 (Quarter) a

Related Keywords

Australia ,Cambridge ,Cambridgeshire ,United Kingdom ,Florida ,United States ,Miami Beach ,Adelaide ,South Australia ,Canada ,Australian ,American ,Kadrian Hinton ,Suzanne Irwin ,Francisco Bejar ,Connor Bernstein ,Alan Fisher ,Tim Cunningham ,Spyros Papapetropoulos ,Danforth Associates ,Company Australian ,Audit Risk Committee ,Securities Exchange Commission ,Maxim Group Healthcare Virtual Conference Panel ,Merck Co Inc ,Cantor Fitzgerald Co ,Drug Administration ,Safety Review Committee ,Bionomics Limited ,American Society Of Clinical Psychopharmacology ,Bionomics Limited Nasdaq ,Nasdaq ,Mental Health ,Quarterly Cashflow ,Post Traumatic Stress Disorder ,Quarterly Cashflow Report ,Cantor Fitzgerald ,American Depositary Shares ,Securities Act ,Sales Agreement ,Clinical Psychopharmacology ,Social Anxiety Disorder ,Maxim Group Healthcare Virtual Conference ,More Critical Than ,Annual Neuropsychiatry Virtual Conference ,Risk Committee ,Non Executive Chair ,Errol De Souza ,Chief Financial Officer ,Vice President ,Bionomics Shares ,Voluntary Sale Facility ,Listing Rule ,Independent Safety Review Committee ,First Patient Dosed ,Cashflow Report ,The Company ,Company ,Atm Program ,Bionomics ,The Quarter ,Announcement ,